Evidence map›Paper›PMID 36248901›Full record

ArticleFrontiers in immunology2022

Complement membrane attack complex is an immunometabolic regulator of NLRP3 activation and IL-18 secretion in human macrophages.

Gisela Jimenez-Duran, Joseph Kozole, Rachel Peltier-Heap, Eleanor R Dickinson, Christopher R Kwiatkowski, Francesca Zappacosta, Roland S Annan, Nicholas W Galwey, Eva-Maria Nichols, Louise K Modis and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Gisela Jimenez-DuranImmunology Network, Immunology Research Unit, GSK, Stevenage, United Kingdom.
Joseph KozoleDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Philadelphia, PA, United States.
Rachel Peltier-HeapDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Stevenage, United Kingdom.
Eleanor R DickinsonDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Stevenage, United Kingdom.
Christopher R KwiatkowskiDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Philadelphia, PA, United States.
Francesca ZappacostaDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Philadelphia, PA, United States.
Roland S AnnanDiscovery Analytical, Medicinal Science and Technology (MST), GSK, Philadelphia, PA, United States.
Nicholas W GalweyResearch Statistics, Development Biostatistics, GSK, Stevenage, United Kingdom.
Eva-Maria NicholsImmunology Research Unit, GSK, Stevenage, United Kingdom.
Louise K ModisImmunology Research Unit, GSK, Stevenage, United Kingdom.
Martha TriantafilouImmunology Network, Immunology Research Unit, GSK, Stevenage, United Kingdom.
Kathy TriantafilouImmunology Network, Immunology Research Unit, GSK, Stevenage, United Kingdom.
Lee M BootyImmunology Network, Immunology Research Unit, GSK, Stevenage, United Kingdom.
Age UK · GBCardiff University · GBUniversity Hospital of Wales · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is an ancient and critical part of innate immunity. Recent studies have highlighted novel roles of complement beyond lysis of invading pathogens with implications in regulating the innate immune response, as well as contributing to metabolic reprogramming of T-cells, synoviocytes as well as cells in the CNS. These findings hint that complement can be an immunometabolic regulator, but whether this is also the case for the terminal step of the complement pathway, the membrane attack complex (MAC) is not clear. In this study we focused on determining whether MAC is an immunometabolic regulator of the innate immune response in human monocyte-derived macrophages. Here, we uncover previously uncharacterized metabolic changes and mitochondrial dysfunction occurring downstream of MAC deposition. These alterations in glycolytic flux and mitochondrial morphology and function mediate NLRP3 inflammasome activation, pro-inflammatory cytokine release and gasdermin D formation. Together, these data elucidate a novel signalling cascade, with metabolic alterations at its center, in MAC-stimulated human macrophages that drives an inflammatory consequence in an immunologically relevant cell type.

Indexed as

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinComplement Membrane Attack ComplexHumansInterleukin-18Interleukin-1betaMacrophagesComplement Membrane Attack ComplexInflammasomesInterleukin-18Interleukin-1betaNLR Family, Pyrin Domain-Containing 3 Proteincomplementimmunometabolismmacrophagemitochondrial dysfunctionNLRP3 inflammasomereactive oxygen species

Identifiers

PMID36248901
PMCPMC9554752
OpenAlexW4297491299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.